giredestrant: Clinical Trials

11 trials of giredestrant, newest first

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

5 recruiting, 3 completed, 1 active not recruiting, 1 not yet recruiting. 11 Phase 1, 5 Phase 2.

By phase and status

Phase	Trials	Status
Phase 1	11	Recruiting 5, Completed 3, Active not recruiting 1, Not yet recruiting 1, Terminated 1
Phase 2	5	Recruiting 5

Follow giredestrant: new trials by email Literature Review of giredestrant trials Research Report on giredestrant

Trials (filtered) newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Study to Evaluate the Effects of GDC-4198 in Combination With Letrozole, Fulvestrant, or Giredestrant in Participants With Locally Advanced or Metastatic Hormone Receptor-Positive, HER2-Negatve Breast Cancer GDC-4198, Fulvestrant, Letrozole - Advanced or Metastatic Breast Cancer	Phase 1	Not yet recruiting	Genentech, Inc.	165	2026-12-15	2026-11-05
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer GDC-0587, Giredestrant, Omeprazole - Breast Cancer	Phase 1	Terminated	Genentech, Inc.	3	2026-01-13	2026-08-21
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer GDC-4198, Giredestrant, Abemaciclib - Breast Cancer	Phase 1 / Phase 2	Recruiting	Genentech, Inc.	285	2025-10-07	2026-10-26
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer Atezolizumab - 28 Day Cycle, Bevacizumab, Ipatasertib - Endometrial Cancer	Phase 1 / Phase 2	Recruiting	Alliance Foundation Trials, LLC.	148	2021-10-20	2026-04-01
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer Giredestrant, Abemaciclib, Ipatasertib - Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer	Phase 1 / Phase 2	Recruiting	Hoffmann-La Roche	316	2021-06-22	2026-11-03
Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-GDC-9545 Following a Single Oral Dose (Part 1) and to Evaluate the Absolute and Relative Bioavailability of Oral Capsule Formulations of GDC-9545 (Part 2) in Healthy Female Subjects of Non-Childbearing Potential [14C]-GDC-9545, GDC-9545 Solution for Infusion, GDC-9545/F12 Capsule - Healthy Volunteers	Phase 1	Completed	Genentech, Inc.	16	2021-01-07	2023-02-02
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors PF-07220060, Letrozole, Fulvestrant - Liposarcoma, Prostate Cancer	Phase 1 / Phase 2	Recruiting	Pfizer	430	2020-09-23	2026-10-28
Evaluation of the Relative Bioavailability and Food Effect of GDC-9545 in Healthy Females of Non-Childbearing Potential GDC-9545 Tablet, Fasted: Treatment A, GDC-9545 Capsule, Fasted: Treatment B, GDC-9545 Capsule, Fed: Treatment C - Healthy Volunteers	Phase 1	Completed	Genentech, Inc.	18	2020-03-06	2021-04-28
A Study of Giredestrant (GDC-9545) in Postmenopausal Women With Stage I-III Operable, Estrogen Receptor-Positive Breast Cancer Giredestrant, Surgery - Breast Cancer	Phase 1	Completed	Genentech, Inc.	75	2019-07-26	2023-03-10
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer Capecitabine, Atezolizumab, Ipatasertib - Metastatic Breast Cancer	Phase 1 / Phase 2	Recruiting	Hoffmann-La Roche	1132	2018-03-30	2026-10-09
A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer GDC-9545, Palbociclib, LHRH Agonist - Breast Cancer	Phase 1	Active not recruiting	Genentech, Inc.	181	2017-11-24	2026-08-13

Conditions studied

Sponsors

Countries

Results publications

NIH funding